Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1114281 | 0.84 | RXFP1 (0.33) | DHFRALDH1A1PDGFRBKDR | |
| SCHEMBL15814443 | 0.80 | NUDT1 (0.33) | DHFRALDH1A1 | |
| SCHEMBL854982 | 0.80 | NUDT1 (0.35) | — | |
| SCHEMBL623299 | 0.79 | KDM4E (0.39) | — | |
| SCHEMBL13449514 | 0.79 | NUDT1 (0.33) | — | |
| SCHEMBL15676427 | 0.78 | KDM4E (0.38) | — | |
| SCHEMBL28346588 | 0.77 | ADORA1 (0.46) | — | |
| SCHEMBL30881090 | 0.75 | DGAT1 (0.33) | PDGFRBKDR | |
| SCHEMBL18302169 | 0.75 | PDGFRB (0.34) | PDGFRBKDR | |
| SCHEMBL2674979 | 0.75 | PDGFRB (0.39) | ALDH1A1PDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3230289-B1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C]PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LTD (IN) | 2019-08-14 | — | — | EP | disclosed |
| US-10106554-B2 | 7-(morpholinyl)-2-(N-piperazinyl) methyl thieno [2, 3-C] pyridine derivatives as anticancer drugs | NATCO PHARMA LIMITED (IN) | 2018-10-23 | — | — | US | disclosed |
| US-20170320891-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LIMITED (IN) | 2017-11-09 | — | — | US | disclosed |
| US-20170320891-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LIMITED (IN) | 2017-11-09 | — | — | US | disclosed |
| US-20170320891-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LIMITED (IN) | 2017-11-09 | — | — | US | disclosed |
| US-20140309221-A1 | METHOD OF INHIBITING HAMARTOMA TUMOR CELLS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309221-A1 | METHOD OF INHIBITING HAMARTOMA TUMOR CELLS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309221-A1 | METHOD OF INHIBITING HAMARTOMA TUMOR CELLS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| EP-2673268-A1 | METHOD OF INHIBITING HAMARTOMA TUMOR CELLS | Dana-Farber Cancer Institute, Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8563549-B2 | Pyrimidine derivatives used as PI-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| EP-2118087-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-11-18 | — | — | EP | disclosed |
| EP-1989201-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| EP-1984350-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | Novartis AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| WO-2008098058-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106554-B2 | 7-(morpholinyl)-2-(N-piperazinyl) methyl thieno [2, 3-C] pyridine derivatives as anticancer drugs | PRMT7, CDK7, CASP7 | DHFR 69/4885ALDH1A1 1710/4885PDGFRB 1023/4885 |
| US-20170320891-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | PRMT7, CDK7, CASP7 | DHFR 69/4885ALDH1A1 1710/4885PDGFRB 1023/4885 |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | PI4KA, PI4KB, PI4K2A | DHFR 3744/4885ALDH1A1 4631/4885PDGFRB 588/4885 |
| US-20140309221-A1 | METHOD OF INHIBITING HAMARTOMA TUMOR CELLS | PHPT1, VHL, SDHA | DHFR 27/4885ALDH1A1 528/4885PDGFRB 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.